Evidence map›Paper›PMID 39460282›Full record

ArticleVaccines2024

Enhanced Expression of the

Antonia Radaelli, Carlo Zanotto, Chiara Brambilla, Tommaso Adami, Carlo De Giuli Morghen

Abstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Antonia RadaelliDepartment of Medical Biotechnologies and Translational Medicine, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy.ORCID 0000-0002-5683-6216
Carlo ZanottoDepartment of Medical Biotechnologies and Translational Medicine, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy.ORCID 0000-0003-0222-6102
Chiara BrambillaDepartment of Medical Biotechnologies and Translational Medicine, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy.ORCID 0009-0006-6685-5767
Tommaso AdamiDepartment of Medical Biotechnologies and Translational Medicine, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy.ORCID 0009-0006-5423-0751
Carlo De Giuli MorghenDepartment of Pharmacy, Faculty of Pharmacy, Catholic University "Our Lady of Good Counsel", Rr. Dritan Hoxha, 123, 1001 Tirana, Albania.

Funding

North Atlantic Treaty Organization C5486
6 · The paper itself

Abstract

The use of Vaccinia virus (VACV) as a preventive vaccine against variola, the etiological agent of smallpox, led to the eradication of smallpox as a human disease. The L1 protein, a myristylated transmembrane protein present on the surface of mature virions, plays a significant role in infection and morphogenesis, is well-conserved in all orthopoxviruses, and is the target of neutralizing antibodies. DNA recombinant vaccines expressing this protein were successfully used, but they showed lower efficacy in non-human and human primates when used alone, and viral-vectored fowlpox vaccines were already proved to increase immunogenicity when used as a boost. Here, we constructed a novel fowlpox-based recombinant (FP

Indexed as

fowlpox virus recombinant vaccinesimmunogenicity enhancementmonkeypox virustissue plasminogen activator signal sequence (tPA)vaccinia virus L1 protein

Identifiers

PMID39460282
PMCPMC11511345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.